ASCO 2020 – Osimertinib improves DFS after surgery for localized NSCLC


  • Kelli Whitlock Burton
  • Oncology Conference reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients with resected localized primary nonsquamous stage non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations had significantly better disease-free survival (DFS) than those who received placebo.

Why this matters

  • Adjuvant chemotherapy is the current standard of care in patients with resected stage II-III NSCLC and select stage IB patients, but high recurrence rates suggest additional therapies are needed.

Study design

  • Phase 3, double-blind, randomized ADAURA trial.
  • 682 patients with surgically resected primary nonsquamous stage IB/II/IIIA NSCLC with EGFR mutations received osimertinib (n=339) or placebo (n=343).
  • Funding: AstraZeneca.

Key results

  • In patients with stage II-IIIA, DFS was significantly better with osimertinib (HR, 0.17; P<.0001>
  • 2-year DFS: 90% in the osimertinib group vs 44% in the placebo group.
  • In the overall population, 2-year DFS was 89% in the osimertinib group and 53% in the placebo groups.
  • Overall survival was immature (4% maturity) with 29 deaths (osimertinib n=9; placebo n=20).
  • No new safety issues.
  • Limitations

    • None included.